Today’s Top Three in Pharma 043009

Ortho-McNeil launches Facebook page for adult ADHD sufferers.
Lilly and Amylin teaming up to produce once-a-week diabetes pen.
Good stuff on Merck KGaA’s oral MS drug. That company and Novartis both bringing groundbreaking new ones to market.
LATE BREAKING – big cuts at Seattle’s ZymoGenetics.
And, hey, why not a bit of speculation to spice up the day? Should [...]

Read Full Post »

The Female Orgasmatic

There are reasons why people don’t think highly of pharmaceutical companies. One of them is the misguided race to promote “female sexual dysfunction”, and to find a “cure.”
While there may indeed be biological reasons for certain sexual difficulties in women, the notion that some pill is going to fan the flames of desire and be [...]

Read Full Post »

A Breath of Training Fresh Air

I like this approach, taken by Daiichi-Sankyo. A lot. – Designed to improve a reps’ knowledge and understanding of hypertension and related cardiovascular disease, ASH’s Hypertension Accreditation Program will train more than 700 Daiichi sales team members in the first year of the program…To achieve accreditation, sales reps will undergo rigorous training (approximately 10 hours [...]

Read Full Post »

Today’s Top Three in Pharma 042909

“Physicians and medical institutions should shun gifts, reps, samples and ghostwriting, said the Institute of Medicine’s conflict of interest committee in its full recommendations.” More…
Who needs reps? Doctors comfortable with ePromotion. Hmmm..
Sanofi bags some experimental drugs in the pipeline. Formerly in the pipeline.
Novartis gets ongoing encouraging results for experimental MS oral drug.
Pfizer to former biotech [...]

Read Full Post »

After Hours 042709

The moon, in stunning detail. Plenty awesome.
Keeping up with the space theme, some fabulous close-ups of Saturn from the Cassini spacecraft.
A great variety of pics from Earth day, biggie-size.
Awesome, “flowing” shots of slot canyons.
PLUS: Two of the favorite items ever on Amazon (here and here). You have to read the customer reviews. You’ll be rolling [...]

Read Full Post »

Training Need: Business Acumen for Reps/Managers

The days of sending out armies of sales reps equipped with product knowledge and selling skills are over.
In the new environment, healthcare professionals will (rightly) expect representatives from drug companies to provide much greater value on the business level.
Some of Impactiviti’s preferred partners specialize in training offerings to help create more business-savvy and valuable field [...]

Read Full Post »

When Projects go South

I’m a native Northeast guy, but I spent 7 years in the South (Tennessee). I enjoy visiting there when I can. But there’s one time when you really don’t want to head in that direction, and that’s when the training project you’re working on with a vendor goes south!
It happens. More often than anyone likes [...]

Read Full Post »

Today’s Top Three in Pharma 042309

FDA extends review of AstraZeneca/BMS experimental diabetes drug Onglyza.
Teva blocked from launching generic form of Lilly’s Evista; also rumored to be eyeballing a purchase of Watson.
Roche/Genentech’s Avastin misses the mark in colon cancer study.
PLUS – you want pharma growth? Sanofi says, Go East! (I know another big pharma also ramping up very rapidly in China…)
——
Subscribe [...]

Read Full Post »

Social Pharmer Un-conference: A re-cap (sort of)

Yesterday I had the privilege of attending the first (I suspect there will be more!) one-day Social Pharmer un-conference, held in Cambridge, MA, in conjunction with Health Camp Boston.
I’m sure that others will focus on the content, and much of the material can be digested in tidbit size through Twitter tweets under the hashtag #SocPharm. [...]

Read Full Post »

Social Pharmer: Immediate Social Networking Biz Applications?

On April 21 at 1:00 pm EST, I’ll be leading a discussion about where pharma companies can begin using social networking approaches NOW for clear business applications. And this blog post is appearing at about that time for those who cannot be in Boston for the event, but who’d like to participate via Twitter.
This discussion [...]

Read Full Post »